Corbus PharmaceuticalsCRBP
About: Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Employees: 19
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
95% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 20
21% more call options, than puts
Call options by funds: $22.9M | Put options by funds: $18.9M
0% more funds holding
Funds holding: 107 [Q2] → 107 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 31
5.31% less ownership
Funds ownership: 103.0% [Q2] → 97.69% (-5.31%) [Q3]
51% less capital invested
Capital invested by funds: $498M [Q2] → $243M (-$255M) [Q3]
67% less funds holding in top 10
Funds holding in top 10: 6 [Q2] → 2 (-4) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Piper Sandler Biren Amin 15% 1-year accuracy 3 / 20 met price target | 169%upside $35 | Overweight Initiated | 2 Dec 2024 |
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 105 / 327 met price target | 515%upside $80 | Buy Reiterated | 23 Sept 2024 |